You are here

Takeda to win EU approval for US$62b Shire deal: sources

2018-10-30T023858Z_1006253685_RC1E086A4C10_RTRMADP_3_TAKEDA-PHARMA-RESULTS.JPG
Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its US$62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.

[BRUSSELS] Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its US$62-billion bid for London's Shire, the biggest ever overseas acquisition by a Japanese company, two people familiar with the matter said on Friday.

Last month, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.

Entyvio, a treatment for Crohn's disease and ulcerative colitis, is Takeda's biggest-selling drug.

Shire's shares moved into positive territory in London following the Reuters story, closing up 0.28 per cent. Its US listed shares recovered some earlier losses after the story.

Takeda is looking to the acquisition to boost its late-stage pipeline. Rare disease specialist Shire has seven drug candidates in Phase 3 clinical trials compared to its three. The deal would also make it a global top 10 drugmaker.

Your feedback is important to us

Tell us what you think. Email us at btuserfeedback@sph.com.sg

The EU competition enforcer, which is scheduled to rule on the deal by Nov 20, and Takeda declined to comment. Shire did not immediately respond to a request for comment.

Takeda has already secured unconditional clearance from regulators in the United States, Japan, China and Brazil.

REUTERS

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes